Seaside advances autism drug
Seaside Therapeutics has issued positive results for a second phase 2 clinical trial on its drug candidate to treat autism.
While the first study focused on fragile X syndrome, the most common cause of autism, the second study expanded the indication to a variety of autism spectrum disorders. The company has decided to move forward with phase 3 trials for the potential therapy, called STX209, in both indications. The Cambridge-based biotechnology company said that the study showed a marked improvement in patients’ symptoms, including irritability and social withdrawal.
Read more here: Seaside advances autism drug – Boston Business Journal.
Note: To support the site we make money on some products, product categories and services that we talk about on this website through affiliate relationships with the merchants in question. We get a small commission on sales of those products.That in no way affects our opinions of those products and services.
Share this:
About The Author
Julia Roberts
Julia Roberts is founder of Support for Special Needs and has been a regular contributor since its inception in May 2010. A mom to two kids with special needs, she didn't want other parents to feel what is the often isolating world of raising a child (or two!) with disabilities. Her kids had kidney transplants at the age of eight and will need liver transplants in the future as a result of ARPKD/CHF. They both have vision disorders and learning disabilities.